Mydriaticum (Tropicamide)

Tropicamide blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary muscles. By preventing parasympathetic stimulation, the iris sphincter relaxes, causing pupil dilation, while the ciliary muscle relaxes, leading to loss of accommodation. This dual action produces the desired mydriatic and cycloplegic effects.

The specific dosing regimen for Mydriaticum is determined by the prescribing eye specialist based on the patient’s age, clinical indication, and response. The prescriber will select the appropriate number of drops and timing to achieve adequate pupil dilation while minimizing side effects.

Safety data for tropicamide in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Healthcare providers should weigh potential benefits against risks and consider alternative options when treating pregnant or nursing individuals.

To request Mydriaticum, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Tropicamide is a short‑acting anticholinergic mydriatic, offering rapid onset and a duration of 4–6 hours, which is shorter than agents like phenylephrine or cyclopentolate. This makes it suitable for routine examinations where brief dilation is preferred, while longer‑acting agents may be chosen for therapeutic purposes.

Mydriaticum should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct light and moisture. Do not freeze. Ensure the vial is tightly sealed to maintain sterility until use.

Mydriaticum is applied topically to the eye as an ophthalmic solution. The prescriber will instruct the patient on the number of drops per eye and the interval between doses, typically instilling one or two drops and waiting a few minutes before any additional ocular medication.

The most serious risks include acute angle‑closure glaucoma, especially in patients with narrow anterior chamber angles, and systemic anticholinergic effects such as rapid heart rate, dry mouth, or confusion. Prompt medical attention is required if severe eye pain, vision loss, or systemic symptoms develop.

Mydriaticum should be avoided in individuals with known hypersensitivity to tropicamide or other anticholinergics, patients with uncontrolled narrow‑angle glaucoma, and those in whom pupil dilation could exacerbate ocular conditions. A thorough ocular assessment by an eye care professional is essential before use.